For years, the pitch for NAD+ boosters has rested on one simple claim: NAD declines with age, so you should replace what you are losing. A new paper in Nature Metabolism challenges the premise, at least when NAD is measured in human blood. In healthy adults, whole-blood NAD did not fall with age. What did predict lower levels was cardiovascular disease and hypertension.
What the Study Actually Found
The research, led by Romenskaja-Avgul, Stakelytė and Laurynėnas, analyzed 1,340 whole-blood NAD measurements from 1,068 adults. The aim was to settle a long-running dispute over whether blood NAD changes with ageing or with disease.
The results split into two findings.
- In healthy individuals, NAD does not decline with age. Levels stayed stable in males and increased in females.
- In chronic disease, NAD is lower. The reductions were linked specifically to cardiovascular disease and hypertension.
The authors summarize this as whole-blood NAD tracking cardiovascular disease rather than chronological age.
Why This Cuts Against the Popular Narrative
The idea that NAD falls steadily through adulthood is one of the most repeated claims in longevity circles. It is often traced to tissue and animal studies, along with smaller human datasets, and it underpins a large market for NAD precursors such as NR and NMN, plus IV NAD+ clinics.
This study does not show that tissue NAD never declines. It measures whole blood, a single compartment, and blood is not muscle, brain, liver or fat. But the dataset is large for this field, and it directly contradicts the assumption that a blood-based NAD reading drops simply because you have had more birthdays.
The practical implication is that age alone may be a poor reason to assume your blood NAD is low. If a person is healthy, the "you're losing NAD as you get older" argument may not apply to their circulating levels.
The Sex Difference Is Worth Noticing
The sex-specific pattern is one of the more intriguing details. Healthy males stayed stable, while healthy females showed an increase with age. A simple linear-decline model would not predict that. The abstract gives no mechanism, so any explanation, such as hormonal changes, differences in blood composition or shifts in red blood cell content, would be speculation. It does suggest that "NAD and age" is not one universal curve, and that studies pooling men and women together may blur important differences.
Cardiovascular Disease and Hypertension: The Real Signal
The strongest signal in the data is the link between lower whole-blood NAD and cardiovascular disease and hypertension. This fits a broader scientific interest in NAD metabolism and vascular health, since NAD is central to cellular energy handling and redox balance, and the cardiovascular system is metabolically demanding.
But the direction of the relationship matters, and this study cannot resolve it. Lower NAD might contribute to disease. Disease processes, inflammation, medications or lifestyle factors tied to illness might lower NAD. Or a third factor might drive both. The authors are explicit on this point.
The Critical Caveat: No Proof of Treatment
The authors state plainly that the research was not designed to investigate causality. Their data therefore do not provide direct evidence that NAD supplementation may serve as a treatment for cardiovascular disease or hypertension.
This is easy to overlook in a field that moves quickly from association to product. A low biomarker in sick people does not mean raising the biomarker will make them well. Many biomarkers that track disease turn out to be consequences, not levers. Only interventional trials can show whether restoring NAD changes outcomes.
Practical Takeaways for Biohackers
For people who track their own biomarkers, the study suggests a few ways to think about NAD data.
- Don't assume age means low NAD. If you are healthy, a decline in blood NAD is not a given just because you are older.
- Treat a low reading as a possible health flag, not an age verdict. A low whole-blood NAD might be worth discussing with a clinician alongside blood pressure, lipids and other cardiovascular markers.
- Context matters more than a single number. Sex, health status and measurement method all affect interpretation. This study used whole blood, and results may not translate to other sample types or to tissue levels.
- Be skeptical of supplement logic built on age alone. "I'm 50, so I need NAD precursors" is not supported by these blood data.
- Don't self-treat cardiovascular conditions with NAD products. The authors say the data do not support supplementation as a treatment for these conditions. Standard medical care for hypertension and heart disease remains the evidence-based route.
- Consider tracking over time. The study included repeat measurements in some participants, and personal trends may be more informative than a single snapshot.
Limits and Open Questions
Several questions remain open. Whole-blood NAD is dominated by red blood cells, so it may not reflect NAD in the tissues where age-related decline has been proposed. The abstract does not detail the measurement platform, medication effects or participant demographics, so readers should consult the full paper before drawing finer conclusions. And the central question of whether low NAD in cardiovascular disease is cause, consequence or bystander is untouched.
The Bottom Line
This study shifts the question from "does NAD fall with age?" to "what does a low blood NAD tell us about health?" The answer, in this dataset, is that it may say more about your cardiovascular status than your birth year. That makes whole-blood NAD a potentially interesting marker, but not yet a proven therapeutic target. For anyone weighing supplements, the honest message is that the age-decline argument is weaker than commonly claimed, and the disease-treatment argument still needs clinical trials.